Shares of San Diego-based medical instruments maker
) reached a new 52-week high of $35.97 in mid-day trading
yesterday. Shares of the company closed at $34.03 on the same
day, representing a solid one-year and year-to-date returns of
148.2% and 145.7%, respectively.
ANGIODYNAMICS (ANGO): Free Stock Analysis
NATUS MEDICAL (BABY): Free Stock Analysis
CYNOSURE INC-A (CYNO): Free Stock Analysis
DEXCOM INC (DXCM): Free Stock Analysis Report
To read this article on Zacks.com click here.
DXCM has a market cap of $2.4 billion. Average volume of shares
traded over the last three months stood at approximately 595.9K.
Shares of DexCom started escalating following its promising third
quarter results on Nov 6. The company reported a narrower loss of
$6.0 million or 8 cents per share in the quarter compared with
$17.3 million or 25 cents in the comparable quarter of 2012 as
well as the Zacks Consensus Estimate of a loss of 13 cents.
DXCM's total revenues surged 85.7% to $42.9 million, topping the
Zacks Consensus Estimate of $36.0 million, on product revenues
that more than doubled to $42.5 million from $21.1 million a year
ago. Meanwhile, development grant and other revenues plunged
80.0% to $0.4 million from $2.0 million in the prior year
Product gross profit more than tripled to $27.7 million in the
quarter from $7.7 million in the third quarter of 2012. Total
gross profit increased in the same magnitude to $27.6 million
from $8.4 million a year ago while gross margin improved
significantly to 64.3% from 36.4% in the 2012-quarter.
DexCom had cash and cash equivalents of $33.4 million as of Sep
30, 2013, significantly up from $8.1 million as of Dec 31, 2012.
Total debt remained flat at $7.0 million as of Sep 30, 2013
compared with the same as of Dec 31, 2012.
Currently, DXCM retains a Zacks Rank #2 (Buy). Other medical
instrument stocks that are also worth a look include
Natus Medical Inc.
). Cynosure and Natus Medical carry a Zacks Rank #1 (Strong Buy)
while AngioDynamics carries a Zacks Rank #2 (Buy).